Apimeds Pharmaceuticals Files S-1 for Public Offering

TL;DR

Apimeds Pharma just filed an S-1, looks like they're gearing up for an IPO.

AI Summary

Apimeds Pharmaceuticals US, Inc. filed an S-1 registration statement on September 25, 2024, to register securities under the Securities Act of 1933. The company, incorporated in Delaware with its principal executive offices in Hopewell, NJ, operates in the Pharmaceutical Preparations industry. Erik Emerson is listed as the Chief Executive Officer and Chief Financial Officer.

Why It Matters

This S-1 filing indicates Apimeds Pharmaceuticals US, Inc. is preparing to go public, which could bring new investment and potentially new treatments to market.

Risk Assessment

Risk Level: medium — As a newly public company, Apimeds Pharmaceuticals US, Inc. faces inherent risks associated with market volatility, regulatory hurdles, and establishing a market presence.

Key Numbers

• 333-282324 — SEC File Number (Identifies the specific SEC registration filing)
• 0001894525 — Central Index Key (Unique identifier for the company in SEC filings)

Key Players & Entities

• Apimeds Pharmaceuticals US, Inc. (company) — Registrant
• September 25, 2024 (date) — Filing date
• Securities Act of 1933 (legal_document) — Governing legislation for registration
• Delaware (jurisdiction) — State of incorporation
• Hopewell, NJ (location) — Principal executive offices
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
• Erik Emerson (person) — Chief Executive Officer and Chief Financial Officer

FAQ

Key Financial Figures

• $8.28 — the United States accounted for $8.28 billion in 2022 and it is expect
• $20.24 — n 2022 and it is expected to hit around $20.24 billion by 2032, expanding at a

Filing Documents

• ea0201124-07.htm (S-1) — 3821KB
• ea020112407ex1-1_apimeds.htm (EX-1.1) — 453KB
• ea020112407ex3-1_apimeds.htm (EX-3.1) — 13KB
• ea020112407ex3-2_apimeds.htm (EX-3.2) — 72KB
• ea020112407ex10-1_apimeds.htm (EX-10.1) — 9KB
• ea020112407ex10-2_apimeds.htm (EX-10.2) — 55KB
• ea020112407ex10-3_apimeds.htm (EX-10.3) — 24KB
• ea020112407ex10-4_apimeds.htm (EX-10.4) — 142KB
• ea020112407ex10-5_apimeds.htm (EX-10.5) — 30KB
• ea020112407ex10-6_apimeds.htm (EX-10.6) — 26KB
• ea020112407ex10-7_apimeds.htm (EX-10.7) — 22KB
• ea020112407ex10-8_apimeds.htm (EX-10.8) — 18KB
• ea020112407ex10-9_apimeds.htm (EX-10.9) — 25KB
• ea020112407ex10-10_apimeds.htm (EX-10.10) — 19KB
• ea020112407ex10-11_apimeds.htm (EX-10.11) — 20KB
• ea020112407ex10-12_apimeds.htm (EX-10.12) — 25KB
• ea020112407ex10-13_apimeds.htm (EX-10.13) — 33KB
• ea020112407ex10-14_apimeds.htm (EX-10.14) — 80KB
• ea020112407ex10-15_apimeds.htm (EX-10.15) — 97KB
• ea020112407ex10-16_apimeds.htm (EX-10.16) — 16KB
• ea020112407ex10-17_apimeds.htm (EX-10.17) — 12KB
• ea020112407ex10-18_apimeds.htm (EX-10.18) — 16KB
• ea020112407ex10-19_apimeds.htm (EX-10.19) — 24KB
• ea020112407ex10-20_apimeds.htm (EX-10.20) — 19KB
• ea020112407ex10-21_apimeds.htm (EX-10.21) — 12KB
• ea020112407ex10-22_apimeds.htm (EX-10.22) — 14KB
• ea020112407ex10-23_apimeds.htm (EX-10.23) — 11KB
• ea020112407ex21-1_apimeds.htm (EX-21.1) — 1KB
• ea020112407ex23-1_apimeds.htm (EX-23.1) — 2KB
• ea020112407ex99-1_apimeds.htm (EX-99.1) — 107KB
• ea020112407ex-fee_apimeds.htm (EX-FILING FEES) — 15KB
• tapimeds_logo.jpg (GRAPHIC) — 91KB
• tefhutton_logo.jpg (GRAPHIC) — 21KB
• ttable_01.jpg (GRAPHIC) — 994KB
• tflowchart_001.jpg (GRAPHIC) — 266KB
• 0001213900-24-081766.txt ( ) — 7122KB

RISK FACTORS

RISK FACTORS   9 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS   46

USE OF PROCEEDS

USE OF PROCEEDS   49 DIVIDEND POLICY   50 CAPITALIZATION   51

DILUTION

DILUTION   52 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   54

BUSINESS

BUSINESS   64 MANAGEMENT   89

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION   95 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS   100 PRINCIPAL STOCKHOLDERS   104

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK   105 SHARES ELIGIBLE FOR FUTURE SALE   107 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS   109

UNDERWRITING

UNDERWRITING   112 LEGAL MATTERS   120 EXPERTS   120 WHERE YOU CAN FIND MORE INFORMATION   120 INDEX TO FINANCIAL STATEMENTS   F-1 You should rely only on the information contained in this prospectus. We and the underwriters have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We and the underwriters are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. No action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes included elsewhere in this prospectus, before ma

View Full Filing

View this S-1 filing on SEC EDGAR